Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1, New Zealand.
Rheumatology (Oxford). 2005 Jun;44(6):813-8. doi: 10.1093/rheumatology/keh538. Epub 2005 Feb 3.
To determine the effects of once-weekly oral alendronate on indices of bone size, density and resorption in children with chronic illness being treated with glucocorticoids.
Twenty-two children with chronic illness treated with prednisone were randomized to receive 1 year's treatment with either once-weekly oral placebo or alendronate (1-2 mg/kg body weight) in a double-blind study. The main outcome measures were changes in lumbar spine and femoral shaft size and volumetric density (measured by dual energy X-ray absorptiometry) and N-telopeptide excretion (a marker of bone resorption).
Once-weekly alendronate was well tolerated, and there were no major adverse events. In both groups bone size and bone mineral content increased through growth. Volumetric bone density of the lumbar spine increased significantly in the alendronate group (P = 0.013), but not in the placebo group. There were no differences between the groups in growth in the cortical width of the femoral shaft, but the cross-sectional moment of inertia per unit length-a derived estimate of mechanical strength-increased significantly in the alendronate group (P = 0.014) but not in the placebo group. Urine N-telopeptide excretion was suppressed significantly in the alendronate group (P = 0.007) but not in the placebo group. Height velocity was positively correlated with changes in both lumbar spine area and the total width of the femoral shaft (P = 0.015, P = 0.026, respectively).
Once-weekly oral alendronate is well tolerated, suppresses bone resorption and may improve volumetric bone density at the lumbar spine and mechanical strength of the femoral shaft in children with chronic illness taking glucocorticoids. It does not affect bone growth. Larger controlled studies are needed to determine if these changes translate into reduced fracture incidence or greater peak bone mass. This study highlights the importance of differentiating between changes in bone size and changes in volumetric bone density in assessing bone in children, and also having control subjects in intervention studies.
确定每周一次口服阿仑膦酸钠对正在接受糖皮质激素治疗的慢性病患儿的骨大小、密度及吸收指标的影响。
在一项双盲研究中,将22名接受泼尼松治疗的慢性病患儿随机分为两组,分别接受为期1年的每周一次口服安慰剂或阿仑膦酸钠(1 - 2mg/kg体重)治疗。主要观察指标为腰椎和股骨干大小及体积密度的变化(通过双能X线吸收法测量)以及N - 端肽排泄量(骨吸收标志物)。
每周一次口服阿仑膦酸钠耐受性良好,未发生重大不良事件。两组患儿的骨大小和骨矿物质含量均随生长而增加。阿仑膦酸钠组腰椎的体积骨密度显著增加(P = 0.013),而安慰剂组未增加。两组股骨干皮质宽度的生长无差异,但阿仑膦酸钠组单位长度的截面惯性矩(机械强度的派生估计值)显著增加(P = 0.014),安慰剂组未增加。阿仑膦酸钠组尿N - 端肽排泄量显著降低(P = 0.007),安慰剂组未降低。身高增长速度与腰椎面积和股骨干总宽度的变化呈正相关(分别为P = 0.015,P = 0.026)。
每周一次口服阿仑膦酸钠耐受性良好,可抑制骨吸收,并可能改善正在服用糖皮质激素的慢性病患儿的腰椎体积骨密度和股骨干机械强度。它不影响骨骼生长。需要进行更大规模的对照研究来确定这些变化是否能转化为骨折发生率降低或更高的峰值骨量。本研究强调了在评估儿童骨骼时区分骨大小变化和体积骨密度变化以及在干预研究中设置对照受试者的重要性。